Bioengineering

Siegfried Remains Focused

Published in Medical Patent Law Weekly, September 5th, 2007

During the first half of 2007, the Siegfried Group (SWX: SFZN) attained revenues of CHF 157.8 million, an increase of 8.6 % over the same period last year. Operating profit (EBIT) reached CHF 21.4 million, 17.5 % more than in the first six months of 2006. Net profit of CHF 45.4 million were unusually high due to the sale of the Sidroga Division and other divestments.

The Siegfried Actives Business Unit, a manufacturer of active pharmaceutical ingredients, generated most of the revenue increase. Siegfried Generics was able to increase revenue despite a difficult market environment

Business Unit Siegfried Actives

During the first...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly

Source: Medical Patent Law Weekly (2007-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry